It is known that, in the case of NSCLC, a number of mutations in the EGFR are correlated with the efficacy of the molecularly-targeted drug Gefitinib (Iressa) (AstraZeneca, London, UK), which is targeting the EGFR molecule [36]. Here, EGFR is linked to non-small cell lung carcinoma.